# US 2022/0276226 A1 · Multikinase degraders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276226 A1
- Document ID: US20220276226A1
- Status: Published application
- Kind: A1
- Application number: 17/631,003
- Filed: 2020-07-28
- Published: 2022-09-01
- Earliest claimed: 2019-07-31
- Assignees: University of Houston System
- Applicants: University of Houston System
- Inventors: Alexander STATSYUK; Sandipan Roy CHOWDHURY
- Web page: https://patentgrep.com/patent/US20220276226A1

## CPC

- A61P 35/00: Antineoplastic agents
- G01N 33/5011: {for testing antineoplastic activity}
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 401/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Multikinase degraders described herein contain on one end a Von Hippel-Lindau (VHL) E3 ligase ligand or cereblon E3 ligase recruiter moiety, which bind to the VHL or cereblon E3 ubiquitin ligase (defined as a ubiquitin ligand binding moiety or ULM group), respectively, and on the other end a promiscuous kinase ligand that binds a target protein kinase (defined as a protein/polypeptide targeting moiety or PTM group), such that the target protein is in close proximity to the ubiquitin ligase. This leads to the ubiquitination and subsequent degradation (and inhibition) of the target protein. Specific present multikinase degraders as shown bind about 360 out of 400 tested kinases, showing that they are much more general kinase binders and degraders than any previously reported.

## Claims

### Claim 1

A multikinase degrader, comprising:
a ubiquitin E3 ligase ligand binding moiety (ULM); and
a protein or polypeptide targeting moiety (PTM).

### Claim 2 (depends on 1)

The multikinase degrader of claim 1, wherein the ubiquitin ligand binding moiety (ULM) comprises a Von Hippel-Lindau (VHL) E3 ligase ligand or a cereblon E3 ligase recruiter moiety.

### Claim 3 (depends on 1)

The multikinase degrader of claim 1, wherein the ubiquitin ligand binding moiety (ULM) comprises a cereblon E3 ligase recruiter moiety, and wherein the cereblon E3 ligase recruiter moiety is a thalidomide.

### Claim 4 (depends on 1)

The multikinase degrader of claim 1, wherein the protein or polypeptide targeting moiety (PTM) comprises a compound having a structure of:

### Claim 5 (depends on 1)

The multikinase degrader of claim 1, further comprising polyethylene glycol (PEG).

### Claim 6 (depends on 5)

The multikinase degrader of claim 5, wherein the polyethylene glycol (PEG) comprises from 1 to 4 repeating units.

### Claim 7 (depends on 1)

A method for determining a target kinase for therapeutic applications, comprising:
treating cells in an assay with the multikinase degrader of claim 1 to produce treated cells;
monitoring degradation of kinases in the treated cells;
identifying affected cells in the treated cells, wherein the affected cells have at least one degraded kinase; and
identifying the degraded kinase in the affected cells, wherein the degraded kinase is determined to be a target kinase for therapeutic applications.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapeutic applications comprise treatment or prevention of cancer, an autoinflammatory disorder, or a neurodegenerative disorder.

### Claim 9

A multikinase degrader having a structure of:
wherein n is 1 to 4.

### Claim 10 (depends on 9)

A method for determining a target kinase for therapeutic applications, comprising:
treating cells in an assay with the multikinase degrader of claim 9 to produce treated cells;
monitoring degradation of kinases in the treated cells;
identifying affected cells in the treated cells, wherein the affected cells have at least one degraded kinase; and
identifying the degraded kinase in the affected cells, wherein the degraded kinase is determined to be a target kinase for therapeutic applications.

### Claim 11 (depends on 10)

The method of claim 10, wherein the therapeutic applications comprise treatment or prevention of cancer, an autoinflammatory disorder, or a neurodegenerative disorder.

### Claim 12

A multikinase degrader having a structure of:
wherein n is 1 to 4.

### Claim 13 (depends on 12)

A method for determining a target kinase for therapeutic applications, comprising:
treating cells in an assay with the multikinase degrader of claim 12 to produce treated cells;
monitoring degradation of kinases in the treated cells;
identifying affected cells in the treated cells, wherein the affected cells have at least one degraded kinase; and
identifying the degraded kinase in the affected cells, wherein the degraded kinase is determined to be a target kinase for therapeutic applications.

### Claim 14 (depends on 13)

The method of claim 13, wherein the therapeutic applications comprise treatment or prevention of cancer, an autoinflammatory disorder, or a neurodegenerative disorder.
